TNF-α Binding Proteins for Immunological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved antibodies capable of binding TNF-α with high affinity and neutralizing its biological activities, which are detrimental in acute and chronic immunological diseases such as rheumatoid arthritis and psoriasis, as existing antibodies are not effective in neutralizing TNF-α with sufficient specificity and potency.
Innovation Solution
Development of a novel family of TNF-α binding proteins, including CDR-grafted, humanized, and antigen-binding portions thereof, with specific amino acid sequences that bind TNF-α, comprising a human acceptor framework and variable domains, capable of neutralizing TNF-α by diminishing its ability to bind to its receptor and reducing associated biological activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies are used to bind TNF-α, then basic binding function is achieved, but neutralization potency and specificity are insufficient
Solution Approach 1:
The patent segments the antibody structure into distinct functional regions: variable domains (VH and VL) for antigen recognition and binding, and constant domains for effector functions. This segmentation allows optimization of each region independently to achieve high neutralization potency while maintaining structural organization. The variable domains contain CDR regions that are specifically engineered for TNF-α binding affinity and specificity.
Solution Approach 2:
The patent applies local quality by creating heterogeneous antibody structures with different domains having specialized functions. The variable domains are designed with specific amino acid sequences for high-affinity TNF-α binding, while constant domains provide structural stability and immune effector functions. This localized functional differentiation enables the antibody to achieve both high potency and appropriate complexity.
2Measurement precision
If antibody specificity for TNF-α is increased, then neutralization effectiveness improves, but development complexity increases
Solution Approach 1:
The patent employs preliminary action through in silico design and selection of variable domain sequences before experimental validation. Computer-based methods are used to predict and select amino acid sequences that will achieve high TNF-α binding specificity, reducing the need for extensive experimental trial-and-error. This preliminary computational work streamlines the development process while ensuring high binding specificity.
Solution Approach 2:
The patent systematically varies amino acid parameters in the variable domains, particularly in the CDR regions, to optimize TNF-α binding specificity. By changing specific amino acid sequences and their compositions, the antibody achieves high specificity for TNF-α while controlling development complexity through targeted sequence optimization rather than exhaustive searching.
3Reliability
If high affinity binding to TNF-α is achieved, then neutralization capacity increases, but manufacturing complexity increases
Solution Approach 1:
The patent uses copying by designing antibodies based on proven structural templates and conserved immunoglobulin frameworks. The variable domains are designed to fit TNF-α using established antibody-antigen interaction principles, allowing replication of successful binding motifs. This templated approach enables high-affinity binding while simplifying manufacturing, as the designs are based on naturally occurring, well-characterized structural elements that are easier to produce.
Solution Approach 2:
The patent optimizes manufacturing ease by carefully selecting amino acid compositions and structural parameters in the antibody sequences. The variable domains are designed with sequences that maintain high TNF-α binding affinity while using amino acids that are easier to express and stabilize during production. This parameter optimization balances binding performance with manufacturability.
Data Source
AI summary
Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.